Induction of cell death and inhibition of cell survival are the main principles of cancer therapy. Resistance to chemotherapeutic agents is a major problem in oncology, which limits the effectiveness of anticancer drugs. A variety of factors contribute to drug resistance, including host factors, specific genetic or epigenetic alterations in the cancer cells and so on. Although various mechanisms by which cancer cells become resistant to anticancer drugs in the microenvironment have been well elucidated, how to circumvent this resistance to improve anticancer efficacy remains to be defined. Autophagy, an important homeostatic cellular recycling mechanism, is now emerging as a crucial player in response to metabolic and therapeutic stresses, which attempts to maintain/restore metabolic homeostasis through the catabolic lysis of excessive or unnecessary proteins and injured or aged organelles. Recently, several studies have shown that autophagy constitutes a potential target for cancer therapy and the induction of autophagy in response to therapeutics can be viewed as having a prodeath or a prosurvival role, which contributes to the anticancer efficacy of these drugs as well as drug resistance. Thus, understanding the novel function of autophagy may allow us to develop a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes in the treatment of cancer patients.

**Review**

**Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment**

X Sui\(^1,5\), R Chen\(^2,5\), Z Wang\(^1,5\), Z Huang\(^2\), N Kong\(^1\), M Zhang\(^2\), W Han\(^1\), F Lou\(^1\), J Yang\(^1\), Q Zhang\(^3\), X Wang\(^*\),\(^1,4\), C He\(^*\),\(^2,4\) and H Pan\(^*\),\(^1,4\)

**Facts**

- The induction of autophagy in response to metabolic and therapeutic stresses can have a prodeath or a prosurvival role, which contributes to the anticancer efficacy of these drugs as well as drug resistance.
- Anticancer drugs induce different effects of autophagy on cell survival in different cancer types.
- Autophagy as a prosurvival and resistance mechanism against chemotherapy treatment.
- Autophagy-mediated cell death mechanism contributes to efficacy of anticancer drugs.
- Targeting autophagy will hopefully provide a promising therapeutic strategy to circumvent resistance and enhance the effects of anticancer therapies for cancer patients.

**Open Questions**

- Whether we should try to enhance or inhibit autophagy in cancer treatment?
- Chloroquine and its derivative: just act as autophagy inhibitors?
- Autophagy is shown to precede apoptosis or act in parallel with this cellular process in addition to be an alternative mechanism to cell death when apoptosis is inhibited. Therefore, the autophagy induction may exert other possibilities, which should be considered in the design of new treatments for the malignancies.

Resistance to anticancer drugs is a common clinical issue in the treatment of patients with cancer. Drug resistance,
intrinsic or acquired, can be attributed to a wide variety of mechanisms including tumor cell heterogeneity, drug efflux and metabolism and tumor microenvironment stress-induced genetic or epigenetic alterations as a cellular response to drug exposure (Figure 1). Among these mechanisms, the response or adaptation of cancer cell itself to anticancer drug-induced tumor microenvironment stresses is a vital cause for chemotherapy resistance.

Autophagy is an evolutionarily conserved catabolic process in which portions of cytosol and organelles are sequestered into a double-membrane vesicle and delivered to the lysosome for bulk degradation. In this review, the term ‘autophagy’ refers to macroautophagy. The role of autophagy in regulating cancer cell death or survival remains controversial. Current evidence supports the idea that constitutive autophagy can act as a cellular housekeeper to eliminate damaged organelles and recycle macromolecules, thus protecting against cancer, particularly during malignant transformation and carcinogenesis. In established tumors, autophagy can function as a prosurvival pathway in response to metabolic stresses such as nutrient deprivation, hypoxia, absence of growth factors and the presence of chemotherapy or some targeted therapies that might mediate resistance to anticancer therapies. Autophagy is also shown to promote cell death following treatment with specific chemotherapeutic agents, either by enhancing the induction of apoptosis or mediating ‘autophagic cell death’.

Although the molecular mechanisms whereby autophagy mediates its effects on both normal and cancer cells are far from complete, various signaling pathways have been implicated in the upregulation or downregulation of autophagy. The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and AMP-activated protein kinase (AMPK) signaling pathways have emerged as the central conduit in the regulation of autophagy (Figure 2). mTOR can be activated by growth factors signal through the class I PI3K/Akt pathway, and inhibited by AMPK and p53. Once activated, mTOR exerts a negative effect on autophagy by phosphorylating a complex of autophagy proteins (ULK1/2), which inhibits the downstream autophagy cascade. In contrast, AMPK can suppress mTORC1 signaling to stimulate autophagy through TSC1/2 phosphorylation. Several of the known tumor-suppressor genes (p53, PTEN, TSC1/TSC2) and tumor-associated genes (p21, AKT) also respectively stimulate or inhibit autophagy. Autophagy is also induced by a variety of metabolic stresses such as endoplasmic reticulum (ER) stress, hypoxia, oxidative stress, expression of aggregate-prone proteins, glucose deprivation and so on. ER stress stimulates autophagy through the PERK/eukaryotic initiation factor 2α (eIF2α) and IRE1/JNK pathways. PERK/eIF2α phosphorylation has been shown to be essential for the transcription of key autophagy-associated genes during ER stress and may mediate the polyglutamine-induced LC3 conversion. The activation of IRE1/JNK promotes phosphorylation of Bcl-2 and p53, resulting in interfering with Bcl-2 binding to Beclin 1 and autophagic cell death in cancer cells. Depletion of nutrients or energy induces autophagy by activating the AMPK pathway or promoting upregulate transcription of certain autophagy genes. The MEK/ERK signaling activation and Rag inactivation contribute to amino acid depletion-induced autophagy. Many anticancer drugs including

Figure 1   A summary of the approaches by which cancer cells become resistant to chemotherapy and various kinds of genotoxic or metabolic stresses
novel targeted therapies stimulate autophagy by inhibiting the PI3K/Akt/mTOR axis or altering genetic/epigenetic phenotype of cancer cells, which provides a survival advantage for struggling tumor cells. The histone deacetylase (HDAC) inhibitors are recently involved in the control of DNA damage response (DDR) and autophagy. SD118-xanthocillin X (1), a novel marine agent extracted from Penicillium commune, induces autophagy through the inhibition of the MEK/ERK pathway. Overall, autophagy is a cell biological process that involves diverse signals that have overlapping functions in autophagy and the control of other cellular stress responses.

**Autophagy in Response to Chemotherapy**

Similar to its potential to either induce cell death or promote cell survival, a growing body of evidence implicates a paradoxical role of autophagy following anticancer treatments, with response increasing or diminishing their anticancer activity. On the one hand, autophagy is activated as a protective mechanism to mediate the acquired resistance phenotype of some cancer cells during chemotherapy. Thus, the inhibition of autophagy can re-sensitize previously resistant cancer cells and augment cytotoxicity of chemotherapeutic agents. On the other hand, autophagy may also play as a death executioner to induce autophagic cell death, a form of physiological cell death that is contradictory to type I programmed cell death (apoptosis) (Figure 3). Based on current genetic and pharmacological studies, it appears that anticancer drugs induce different effects of autophagy on cell survival in different cancer types (Table 1). Here we delineate the possible role of autophagy as a novel target for anticancer therapy.

**Autophagy as a Prosurvival and Resistance Mechanism Against Chemotherapy Treatment**

Recent studies have demonstrated that tumor resistance to anticancer therapies including radiation therapy, chemotherapy and targeted therapies can be enhanced through upregulation of autophagy in different tumor cell lines. Moreover, increasing evidence suggests that autophagy inhibition...
augments cytotoxicity in combination with several anticancer drugs in preclinical models. Several pharmacological compounds and strategies have been reported to inhibit autophagy in vitro and in vivo.

**Antimalarial Drugs**
The only autophagy inhibitors whose effectiveness in vivo and safety in clinical trials have been approved by the FDA are chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) that suppress autophagy by blocking autophagosome fusion and degradation. Both CQ and HCQ have been extensively investigated in preclinical studies or clinical trials. In comparison with CQ, HCQ can be safely dose escalated in cancer patients. Currently, more than 30 phase I/II cancer clinical trials (http://clinicaltrials.gov/) involving CQ or HCQ are open around the world and many of them have evidence of preliminary antitumor activity (Table 2).

Table 1  Autophagy in response to chemotherapy in different types of cancers

| Class | Target | Type of cancer | Autophagy role | Method used to evaluate autophagy | References |
|-------|--------|----------------|----------------|-----------------------------------|------------|
| **Autophagy inducers** | | | | | |
| Aurora kinase A | mTOR | Breast | Prosurvival | siRNA (LC3, Atg5) CQ | 27,28 |
| Suberoylanilide hydroxamic acid (SAHA) | HDAC inhibitor | CML | Prosurvival | 3-MA Bafilomycin A | 29|
| Epirubicin (EPI) | Anthracinelines | Breast | Prosurvival | siRNA (Beclin 1, Atg7) | 34,35 |
| 5-Fluorouracil | Thymidylate synthase inhibitor | Colorectal | Prosurvival | siRNA (Atg7) 3-MA | 37,40-42 |
| Atorvastatin | AMPK | Digestive malignancies | Prosurvival | 3-MA siRNA (Atg5) | 38,39 |
| Iriotocan MAPK14/p38x | Genotoxic stress | Colorectal | Prosurvival | siRNA (Atg5, Atg7) Bafilomycin A | 40,41 |
| Cisplatin | Genotoxic stress | Esophageal | Prosurvival | siRNA (Atg5) Bafilomycin A 3-MA | 42,43 |
| Oxaliplatin | Genotoxic stress | Hepatocellular carcinoma | Prosurvival | CO 3-MA | 44 |
| Bevacizumab | Angiogenesis inhibitor | Hepatocellular carcinoma | Prosurvival | CQ 3-MA | 45 |
| Sorafenib | ER stress | Hepatocellular carcinoma | Prosurvival | CQ | 46 |
| High-mobility group box 1 protein (HMGB1) | Genotoxic stress | CML | Prodeath | siRNA (Beclin 1) | 47,48 |
| Gefitinib or Erlotinib | EGFR tyrosine kinase inhibitor | Lung | Prosurvival | siRNA (Atg5, Atg7) CQ 3-MA | 49,50 |
| Topotecan RAGE | Genotoxic stress | Lung | Prosurvival | CO 3-MA | 51,52 |
| NVP-BEZ235 PI3K/AKT/mTOR inhibitor | Genotoxic or metabolic stress | Renal | Prosurvival | CQ | 53,54 |
| Ursolic acid | Genotoxic stress | Prostate | Prosurvival | siRNA (Atg5, Beclin 1) 3-MA siRNA (Atg5) | 55,56 |
| Imatinib | Tyrosine kinase inhibitor | Glioma | Prosurvival | siRNA (Atg5, Beclin 1) 3-MA siRNA (Atg5) | 57,58 |
| FK-16 | Fragment of LL-37 | Colon | Prodeath | Bafilomycin A 3-MA | 59,60 |
| Temozolomide Mono-Pt | Genotoxic stress | Glioblastoma | Prosurvival | siRNA (Atg5, Beclin 1) 3-MA | 61,62 |
| Cannabinoids | ER stress | Glioma | Prodeath | Bafilomycin A | 63,64 |
| Cannabinoids AMPK | Prodeath | 3-MA | siRNA (Atg1) | 65,66 |
| Cannabinoids AMPK | Prodeath | 3-MA | siRNA (Atg5) 3-MA | 67,68 |
| **Autophagy inhibitors** | | | | | |
| CQ | Lysosomotropic agent | Breast | Prosurvival | Esophageal | 39,40 |
| HCQ | | | | Hepatocellular carcinoma | 41,42 |
| | | | | Lung | 43,44 |
| | | | | Pancreatic | 45,46 |
Table 2 Active clinical trials combining the autophagy inhibitor HCQ with anticancer therapies

| Identifier        | Cancer type                  | Drugs                                         | Phase | Title                                                                 |
|-------------------|------------------------------|-----------------------------------------------|-------|----------------------------------------------------------------------|
| NCT00969306      | NSCLC                        | CQ + cisplatin Etoposide                      | I/II  | Cisplatin, etoposide and escalating CQ in extensive disease NSCLC   |
| NCT00809237      | NSCLC                        | HCQ + gefitinib                               | I/II  | Hydroxychloroquine and gefitinib to treat lung cancer                |
| NCT01649947      | NSCLC                        | HCQ + paclitaxel and carboplatin              | I/II  | Modulation of autophagy in patients with advanced/recurrent non-small-cell lung cancer – phase II |
| NCT00977470      | Advanced NSCLC and (EGFR) mutations | HCQ + erlotinib                              | I/II  | Erlotinib with or without hydroxychloroquine in chemo naive advanced NSCLC and (EGFR) mutations |
| NCT00933803      | Advanced or recurrent NSCLC  | HCQ + carboplatin, paclitaxel, bevacizumaza   |       | Carboptatin, paclitaxel, bevacizumaza and HCQ in advanced or recurrent NSCLC |
| NCT01292408      | Breast cancer                | HCQ                                           | I/I   | Autophagy inhibition using hydroxychloroquine in breast cancer patients |
| NCT00765765      | Breast cancer                | HCQ + ixabepilone                             | I/I   | Ixabepilone and HCQ in metastatic breast cancer                      |
| NCT01023477      | DCIS                         | CQ + tamoxifen                                | I/I   | Neoadjuvant tamoxifen, tamoxifen + CQ, or CQ in DCIS                |
| NCT01510119      | Renal cell carcinoma         | HCQ and RAD001(p.o. 10 mg/day)                | I/I   | Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of RAD001 and hydroxychloroquine in patients with previously treated renal cell carcinoma |
| NCT01144169      | Renal cell carcinoma         | HCQ + high dose interleukin-2 and other systemic therapies | I     | Study of hydroxychloroquine before surgery in patients with primary renal cell carcinoma |
| NCT01550367      | Renal cell carcinoma         | HCQ + IL-2                                    | I/I   | Study of hydroxychloroquine and aldesleukin in renal cell carcinoma patients (RCC) |
| NCT00726596      | Prostate cancer              | HCQ                                           | I/I   | Hydroxychloroquine in treating patients with rising PSA levels after local therapy for prostate cancer |
| NCT01128296      | Pancreatic cancer            | HCQ + gemcitabine                             | I/I   | Study of presurgery gemcitabine + hydroxychloroquine (GHC) in stage IIb or III adenocarcinoma of the pancreas |
| NCT01273805      | Pancreatic cancer            | HCQ                                           | I/I   | Hydroxychloroquine in previously treated patients with metastatic pancreatic cancer |
| NCT01506973      | Pancreatic cancer            | HCQ + gemcitabine/abraxane                   | I/I   | A phase I/II/pharmacodynamic study of hydroxychloroquine in combination with gemcitabine/abraxane to inhibit autophagy in pancreatic cancer |
| NCT01128296      | Pancreatic cancer            | HCQ + gemcitabine                             | I/I   | Study of Pre-surgery Gemcitabine + hydroxychloroquine (GHC) in stage IIb or III adenocarcinoma of the pancreas |
| NCT01494155      | Pancreatic cancer            | HCQ + capecitabine + photon radiation         | II    | Short-course radiation therapy with proton beam capecitabine and hydroxychloroquine for resectable pancreatic cancer |
| NCT01206530      | Colorectal cancer            | HCQ + FOLFOX/ bevacizumab                     | I/II  | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in colorectal cancer      |
| NCT01006369      | Metastatic colorectal cancer | HCQ + capecitabine, oxaliplatin, and bevacizumab | I/II  | Hydroxychloroquine, capecitabine, oxaliplatin, and bevacinumber in treating patients with metastatic colorectal cancer |
| NCT00224978      | Glioblastoma                 | CQ                                            | III   | Adjuvant CQ versus placebo in glioblastoma                          |
| NCT00486603      | Glioblastoma                 | HCQ + temozolomide                            | I/I   | Adjuvant radiation, temozolomide and HCQ in newly resected GBM       |
| NCT00962845      | Melanoma                     | HCQ                                           | No phase specified | Hydroxychloroquine in patients with stage III or Stage IV melanoma that can be removed by surgery |
| NCT00568880      | Multiple myeloma             | HCQ + bortezomib                              | I/II  | Hydroxychloroquine and bortezomib in treating patients with relapsed or refractory multiple myeloma |
| NCT01480154      | Advanced solid tumors or prostate or renal cancer | HCQ + MTD of Akt inhibitor MK2206 (MK-2206) | I     | Phase I study of Akt inhibitor MK2206 and hydroxychloroquine in patients with advanced solid tumors or prostate or renal cancer |
| NCT00909831      | Metastatic solid tumors      | HCQ + temsorilimus                            | I     | Hydroxychloroquine and temsorilimus in treating patients with metastatic solid tumors that have not responded to treatment |
| NCT00813423      | Advanced solid tumors        | HCQ + sunitinib                               | I     | Sunitinib and Hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy |
| NCT01203739      | Advanced solid tumors        | HCQ + vorinostat                              | I     | Vorinostat and HCQ in advanced solid tumors under going radiation therapy for bone metastases |
| NCT01417403      | Solid tumors undergoing radiation therapy for bone metastases | HCQ | I     | Hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases |
| NCT00969306      | Advanced cancer              | HCQ + the highest tolerable dose of sirolimus or vorinostat | I     | Sirolimus or vorinostat and hydroxychloroquine in advanced cancer |
| NCT00141811      | Metastatic or unresectable solid tumors | HCQ + temozolomide                              | I     | Hydroxychloroquine and temozolomide in treating patients with metastatic or unresectable solid tumors |
| NCT01227135      | CML                          | HCQ + imatinib                                | II    | Imatinib mesylate with or without hydroxychloroquine in treating patients with chronic myeloid leukemia |
| NCT01634893      | Ovarian cancer               | HCQ + sorafenib                              | I     | Oral hydroxychloroquine plus oral sorafenib to treat epithelial ovarian cancer FIGO stage III or stage IV, or extraovarian peritoneal carcinoma, or fallopian tube carcinoma failing or ineligible for first-line therapy |

NSCLC, non-small-cell lung cancer; CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; MTD, maximum tolerated dose; HCQ, hydroxychloroquine
Breast cancer. The role of autophagy in breast cancer is an area of active investigation. There is evidence to suggest that epirubicin (EPI) may induce autophagy in human breast cancer MCF-7 cells, resulting in protecting MCF-7 cells from EPI-induced apoptosis. Autophagy is also regarded as a key mechanism of antiestrogen resistance, and blocking autophagy can significantly reduce the emergence of antiestrogen-resistant breast cancer cells. A phase II clinical trial (NCT01292408) is investigating the effects of autophagy inhibition via HCQ on breast cancer patients. The current reports indicate that CQ or HCQ is often used in combination with chemotherapeutic drugs to enhance the efficacy of tumor cell killing; however, its sensitizing effects can also occur independently of autophagy inhibition, which should be considered in the ongoing clinical trials where CQ or HCQ are used in the treatment of breast cancer.

Colorectal cancer. So far, 5-fluorouracil (5-FU), together with other drugs such as oxaliplatin, remains a widely used chemotherapeutic drug in the treatment of a variety of colorectal carcinomas. Previous researches have demonstrated that inhibition of autophagy augments anticancer effects of chemotherapy or some targeted therapies in colorectal cancer. Recently, it has been shown that mitogen-activated protein kinase 14 (MAPK14)/p38α is involved in resistance of colon cancer cells to 5-FU and irinotecan, which triggers survival-promoting autophagy to protect tumor cells against the cytotoxic effects of these drugs. Furthermore, autophagy inhibitor CQ significantly enhances the 5-FU-induced inhibition of tumor growth both in vitro and in vivo. In addition, the combination of FOLFOX/bevacizumab with HCQ is currently being investigated.

Esophageal cancer. The role of autophagy in response to chemotherapy and radiotherapy has been investigated in human esophageal squamous carcinoma cells. Autophagy might play a role as a self-protective mechanism in chemotherapeutic drug-treated esophageal cancer cells, and its inhibition has the potential to improve the efficacy of chemotherapeutic agents such as cisplatin and 5-FU. However, the effect of adding HCQ to conventional therapy for esophageal cancer patients remains unclear.

Glioblastoma. Malignant cell clones resistant to chemotherapy is a key reason for treatment failure in patients with (GBM). When treated with bevacizumab alone, human GBM xenografts show increased autophagic flux and hypoxia-associated growth, which indicates that hypoxia-mediated autophagy promotes tumor cell survival and resistance to antiangiogenic therapy. However, in treatment by combining with the autophagy inhibitor CQ, tumor growth is disrupted, which elucidates a novel mechanism of overcoming resistance to antiangiogenic therapy for GBM. A randomized, double-blind, placebo-controlled trial examines the effect of adding CQ to conventional therapy for GBM. As a result, a median overall survival is 24 months for CQ-treated patients and 11 months for placebo-treated patients. Although it is not statistically different because of the small sample size, the rate of death of patients receiving CQ is prominently lower than controls. Another phase I/II trial concerning dose-limiting toxicities of HCQ with temozolomide (TMZ) and radiation for GBM patients was conducted. The information about the antitumor activity of this combination is underway.

Hepatocellular carcinoma. The combination of autophagy inhibitor and chemotherapy or molecular-targeted therapies has been regarded as a promising therapeutic strategy in the treatment of hepatocellular carcinoma (HCC). Autophagy is functionally activated in HCC cell lines after oxaliplatin treatment, and suppression of autophagy enhances oxaliplatin-induced cell death. Autophagy also contributes to HCC cell survival, and the combined treatment of an autophagy inhibitor and bevacizumab markedly inhibits the growth of HCC. Moreover, the combination of sorafenib with CQ can generate more ER stress-induced cell death in HCC both in vivo and in vitro. Therefore, autophagy inhibition may be a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes in the treatment of HCC.

Leukemia and MCL. Recently, it is reported that high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) molecule, contributes to chemotherapy resistance though the upregulation of autophagy in leukemia. Autophagy inhibitor HCQ is also shown to decrease cell viability of B-chronic lymphocytic leukemia (B-CLL) in a dose- and time-dependent manner. The resistance to Akt/mTOR inhibitors such as everolimus (RAD001) is a significant clinical problem in relapsed mantle cell lymphoma (MCL) patients. Fortunately, pretreatment with HCQ can efficiently overcome this resistance, resulting in the activation of the mitochondrial apoptotic pathway. These data illustrate a strategy of blocking activation of adaptive autophagy pathway to improve treatment outcomes in leukemia and MCL.

Lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in patients with non-small-cell lung cancer (NSCL). Unfortunately, the efficacy of these drugs is limited because of natural or acquired resistance. We report that autophagy can be activated by gefitinib or erlotinib in lung cancer cells, which contributes to the acquired drug resistance of EGFR-TKIs. Furthermore, the antimalaria drug CQ has been shown to enhance chemotherapy and radiation sensitivity in several preclinical models. CQ can not only potentiate the cytotoxicity of topotecan (TPT), but also substantially increase the effects of PI3K/mTOR inhibitor NVP-BEZ235 on induction of apoptosis, inhibition of colony formation and suppression of xenografts in nude mice. A phase I study in advanced NSCL patients with prior clinical benefit from EGFR-TKIs suggests that HCQ with or without erlotinib is safe, and the recommended phase II dose for HCQ with erlotinib 150 mg is 1000 mg daily. Although no difference in survival was elaborated, this study explored the safety of adding HCQ to erlotinib. To assess the efficacy of the combination of HCQ with conventional chemotherapeutics, several clinical trials have been launched.
Pancreatic adenocarcinoma. The cytoprotective role of autophagy in response to chemotherapy has been confirmed in the treatment of pancreatic cancer cells. In agreement with this, Mirzoeva et al. showed that autophagy suppression with CQ promotes antitumor activity of PI3K/mTOR inhibitor for the treatment of pancreatic adenocarcinoma (PDAC) in vitro and in vivo. In addition to CQ, the efficacy and side effects of adding HCQ to conventional therapy are being investigated through several clinical trials.

Prostate cancer and renal cell carcinoma. Several recent studies have indicated that autophagy functions as a survival mechanism to promote chemoresistance in prostate and renal cancer cells. In agreement with this, Mirzoeva et al. showed that autophagy suppression with CQ promotes antitumor activity of PI3K/mTOR inhibitor for the treatment of pancreatic adenocarcinoma (PDAC) in vitro and in vivo. In addition to CQ, the efficacy and side effects of adding HCQ to conventional therapy are being investigated through several clinical trials.

Ovarian cancer. Ovarian cancer has poor prognosis and is frequently resistant to chemotherapy. In this issue, it has been presented that autophagy may be a factor in drug resistance and poor survival in clear cell ovarian cancer patients. Nucleus accumbens-1 (NAC1) can mediate resistance to cisplatin in ovarian cancer cell lines because of activation of autophagy. FTY720, a sphingosine analog, may enhance autophagic flux when treated as a new chemotherapeutic agent for ovarian cancer, and blockade of autophagy aggravates necrotic ovarian cancer cell death in response to FTY720. Now, the effect of combining HCQ with sorafenib is being assessed in FIGO stage III or stage IV ovarian cancer, or extratubal peritoneal carcinoma, or fallopian tube carcinoma failing or ineligible for first-line therapy.

Other Compounds and Strategies

In addition to antimalarial drugs, inhibition of autophagy by either pharmacological approaches or via genetic silencing of autophagy regulatory genes such as Beclin 1, ATG6, ATG5, ATG7 or ATG12 (Table 3) also results in sensitization to a variety of therapeutic agents. Different autophagy inhibitors block the autophagic process at different stages. For example, antimalarial drugs or bafilomycin A1 can inhibit autophagosome fusion with lysosomes and autophagosome degradation in the final stage of autophagy. Class III PI3K inhibitors (3-methyladenine (3-MA), LY294002 and Wortmannin) or knockdown of autophagy regulatory genes are involved in the initiation/expansion stage of autophagy. So far, different autophagy inhibitors or genetic knockout of autophagy regulatory genes have been developed and used in the study of autophagy in cancer chemotherapy.

The Molecular Mechanisms of Protective Autophagy-Mediated Chemoresistance

Although many anticancer therapeutic strategies can induce autophagic cell death, a majority of pertinent studies have been conducted to indicate that autophagy is a protective mechanism associated with increased resistance to chemotherapy. Induction of autophagy has emerged as a drug resistance mechanism that promotes cancer cell survival. There are a number of different mechanisms through which the autophagy-related functions of promoting the survival of tumor cells under the treatment of anticancer drugs (Figure 4).

EGFR signaling. Epidermal growth factor is a key regulatory factor for cell survival. Through its binding to cell surface receptors, EGF can induce the activation of three signaling pathways which are important to the initiation and progression of cancers, Ras/MAPK, PI3K/Akt and JAK/STATs. In the previous study, we confirmed biochemically and morphologically that autophagy can be activated by gefitinib or erlotinib, which was accompanied by the inhibition of the PI3K/Akt/mTOR signaling pathway. Furthermore, blockage of autophagy by the pharmacological inhibitors or gene silence greatly enhanced cytotoxicity of gefitinib or erlotinib. PD168393, an EGFR-TKI, may induce autophagy as a cytostatic but not a cytotoxic response in malignant peripheral nerve sheath tumor (MPNST) cells that was accompanied by suppression of Akt and mTOR activation; moreover, suppression of autophagy by CQ increased caspase activation.
These results indicate that EGFR-TKIs can induce autophagy to promote tumor cell survival in response to targeted chemotherapies, and suppression of autophagy can augment the growth inhibitory effect of these drugs through inhibition of the PI3K/Akt/mTOR signaling pathway.

**PI3K/AKT/mTOR pathways.** In addition to EGFR, the aberrant expression of PI3K/AKT/mTOR is also known to be a key regulator of autophagy. Genetic and pharmacologic autophagy blockade via PI3K/mTOR inhibition may reverse apoptotic resistance and result in significant cell apoptosis. NVP-BEZ235 (BEZ235) is a novel, orally bioavailable dual PI3K/mTOR inhibitor that has exerted a positive effect on autophagy. A recent study suggests that NVP-BEZ235 could induce apoptosis and autophagy; moreover, the combination treatment of NVP with autophagy inhibitors lead to enhanced RCC cell apoptosis. Benzyl isothiocyanate (BITC), a dietary chemopreventive agent, is also found to induce protective autophagy in human prostate cancer cells via inhibition of mTOR signaling pathway, and inhibition of autophagy using 3-MA increased BITC-induced apoptosis. Taken together, targeting PI3K/AKT/mTOR-autophagy pathways displays a well-recognized contribution to overcome chemotherapy resistance and sensitize the tumor cells to anticancer therapy.

**p53, VEGF and MAPK14/p38α signaling.** As a well-known tumor-suppressor gene, p53 is also involved in autophagic regulation. In a mouse model of c-Myc-driven lymphoma, inhibition of autophagy with either CQ or ATG5 shRNA promotes tumor cell death by p53 activation. Stanton et al. show that the VEGF-C/NRP-2 axis is involved in the activation of autophagy, and VEGF-C or NRP-2 depletion contributes to cytotoxic drug-mediated cell death. In addition, the recent studies have provided strong evidence that the MAPK14/p38 signaling is involved in cancer cell resistance to chemotherapy treatment. Paillas et al. investigated the relationship between MAPK14/p38, autophagy and resistance to irinotecan and found that MAPK14/p38 was activated and triggered survival-promoting autophagy to protect tumor cells against the cytotoxic effects of irinotecan. Furthermore, p38MAPK activation is considered a key determinant in the cellular response to 5-FU by controlling the balance between apoptosis and autophagy.

**MicroRNAs.** MicroRNAs (miRNAs) are a class of small, noncoding, endogenously encoded, single-stranded RNAs that regulate gene expression at the post-transcriptional level. Recently, a number of miRNAs have been reported to be deeply involved in resistance or sensitization to chemotherapy. miR-30a, a member of miR-30 family, is a potent inhibitor of autophagy by selectively downregulating Beclin 1 and Atg5 expression. Targeting miR-30a promotes autophagy in response to imatinib treatment and enhances imatinib resistance against CML including primary stem and progenitor cells. Moreover, the blockade of autophagy by miR-30a expression or 3-MA significantly increased cis-DDP-induced apoptosis in cancer cells. Downregulation of miR-199a-5p is observed in most HCC tissues of patients. More importantly, downregulation of miR-199a-5p increases cisplatin resistance by activating autophagy in HCC cells. Cisplatin-induced ATM-dependent phosphorylated (p)-ΔNp63α also plays an important role in chemoresistance. Further research shows that the p-ΔNp63α-induced miR-885-3p might contribute to regulation of apoptosis and/or autophagy in squamous cell carcinoma cells upon cisplatin exposure. Although the relationship between miRNA, autophagy and anticancer therapy resistance is quite complicated, and has not been well elucidated, miRNA may underlie key aspects of chemotherapy resistance.

**Chloroquine and Its Derivative: Just Act as Autophagy Inhibitors?**

CQ and its derivative are currently the only autophagy inhibitors available for clinical treatment of patients. In ongoing cancer treatment clinical trials, HCQ is often used in...
combination with chemotherapeutic drugs, radiotherapy, some targeted therapies and immunotherapy. The treatment of CQ or HCQ can inhibit autophagy-related survival function and exert their anticancer action. However, emerging data indicate that the ability of CQ and its derivative to inhibit the final degradative step of autophagy may not be the only mechanism by which they exert anticancer action; CQ and HCQ may also affect other pathways such as lysosomal membrane permeabilization.

Recently, Maycotte et al.96 reported that CQ could sensitize breast cancer cells to chemotherapy independent of autophagy inhibition, as sensitization was not mimicked by Atg12. Beclin 1 knockdown or bafilomycin A1 treatment, and occurred even in the absence of Atg12. In further studies, CQ and HCQ are shown to function as lysosomotropic agents to promote lysosomal membrane permeabilization (LMP), resulting in signs of apoptosis. The research from Enzenmüller et al.97 shows that PI3K/mTOR inhibitor PI103 enhances the lysosomal compartment by increasing its volume and function, whereas CQ destabilizes lysosomal membranes. Together, CQ overcomes resistance of lung carcinoma cells to PI103-induced autophagy by cooperating with PI103 to trigger lysosome-mediated apoptosis. An additional report suggests that induction of lysosome-mediated apoptosis rather than inhibition of autophagy is critical for the CQ-mediated sensitization to BEZ235-induced apoptosis, as lysosomal enzyme inhibitors significantly decrease BEZ235- and CQ-induced drop of mitochondrial membrane potential (MMP) and caspase-dependent apoptosis.98 Similar to the potential of CQ, HCQ can also induce LMP and Bax/Bak-dependent MMP to trigger caspase activation.99

Taken together, these data indicate that the success of clinical trials using CQ or HCQ combined with other anticancer agents might not be due to CQ or HCQ effects on autophagy induced by chemotherapeutic drugs, as the effect may be mediated by mechanisms other than its inhibition of autophagy. Thus, a better knowledge of the molecular mechanisms and cellular targets of CQ or HCQ should be considered in the ongoing clinical trials where CQ or HCQ are used as autophagy inhibitors.

**Autophagy-Mediated Cell Death Mechanism Contributes to Efficacy of Anticancer Drugs**

Despite its a clear prosurvival role, autophagy has also been viewed as having a prodeath role under certain circumstances and following treatment with a specific set of chemotherapeutic agents, either by enhancing the induction of apoptosis or mediating ‘autophagic cell death’.

Increasing evidence supports that autophagy may mediate cell death in cancer cells which are apoptosis defective or hard to induce. Xiong et al.96 found that autophagic cell death could be induced in PUMA- or Bax-deficient human colon cancer cells after the treatment with 5-FU, consequently followed by decreased cancer proliferation. Suberoylanilide hydroxamic acid (SAHA), a prototype of the newly developed HDAC inhibitor, induces autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells and significantly reduces the tumor growth in vitro and in vivo.97 NVP-BEZ235 is demonstrated to inhibit cisplatin-resistant urothelial cancer cell proliferation by activating autophagic flux and cell cycle arrest, but not inducing apoptotic cell death.98 The antidepressants maprotiline and fluoxetine induce autophagic cell death in drug-resistant Burkitt’s lymphoma (BL), which supports a new mechanistic role for maprotiline and fluoxetine as novel proautophagic agents in the treatment of resistant BL.99 These data indicate that autophagic cell death can be induced as an alternative cell death mechanism when cells fail to undergo apoptosis.

In addition, induction of autophagic cell death is also an alternative approach to kill tumor cells without resistance to anticancer drugs. Ursolic acid promotes cancer cell death by inducing Atg5-dependent autophagy.100 FK-16, derived from the anticancer peptide LL-37, induces caspase-independent apoptosis and autophagic cell death in colon cancer cells.101 The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a GBM cell line.102 Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin.103 Sorafenib and SC-59, which is a novel sorafenib derivative, induce autophagic cell death in hepatocellular carcinoma cells in a dose- and time-dependent manner.104 Recently, cannabinooids have been shown to exert their anticancer activity in glioma, pancreatic cancer and hepatocellular carcinoma via stimulation of autophagy-mediated cell death.105–108 Moreover, the combination of cannabinoids and TMZ strongly activates autophagy-mediated cancer cell death, resulting in a strong antitumoral action in both TMZ-sensitive and TMZ-resistant tumors.109 These studies present new insights into our understanding of the relationship between autophagy and anticancer efficacy and provide a potential therapeutic strategy for the management of some of these tumors.

Several genes and signal pathways contribute to autophagic cell death in cancer cells (Figure 4). The AMPK/AKT1/mTOR axis is critical for regulation of autophagic cell death. Tanshinone IIA induces autophagic cell death via activation of AMPK/ERK and inhibition of mTOR and p70 S6K in KMB-5 leukemia cells.110 Cannabinoids can trigger autophagic cell death in an ER stress and Akt/mTORC1-dependent manner.105–108 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation.111 Diarylquinoline compounds induce a autophagic cell death by inhibiting the Akt pathway and increasing reactive oxygen species in human nasopharyngeal carcinoma cells.112 β-Catenin is also involved in activation of autophagic cell death.113 These results further strengthen the connection between autophagy and anticancer efficacy.

Recently, autophagy has been shown to precede apoptosis or act in parallel with this cellular process in addition to being an alternative mechanism to cell death when apoptosis is inhibited. It has been acknowledged that autophagy precedes caspase-dependent apoptosis.114,115 Several studies demonstrate that autophagy precedes apoptosis and acts as a protective mechanism in cancer cells.116–118 Therefore, the autophagy induction may exert other possibilities, which should be considered in the design of new treatments for these malignancies.

**Conclusions and Perspectives**

Autophagy is a lysosomal degradation process usually activated in response to adverse microenvironmental stresses.
Autophagy itself fulfills a dual role, having tumor-promoting and tumor-suppressing properties. As a response to anticancer treatments, whether autophagy activation leads to cell survival or cell death remains controversial. It is consensus that the outcomes of autophagy activation are highly depended on the tumor types and treatment characteristics.119,120

Resistance to chemotherapy is a major obstacle for the success of cancer therapy. Although the controversy about the prosurvival or anticancer effect of autophagy is still heated, the data in vitro and in vivo seem more to support the idea that autophagy facilitates the cancer cells’ resistance to chemotherapy treatment, and inhibition of autophagy may potentiate the re sensitization of therapeutic-resistant cancer cells to the anticancer drugs.26,121 Several autophagy inhibitors such as CQ and its derivative HCQ have been studied in preclinical models. Although CQ or HCQ augments cytotoxicity in combination with several anticancer drugs, autophagy researchers should be careful when interpreting experiments in which CQ or HCQ treatment is used, as the effect may be mediated by mechanisms other than its inhibition of autophagy.

Currently, the combination of autophagy inhibitors with cytotoxic drugs is attracting more and more attention in cancer therapy. However, the study of the ability of autophagy inhibitors to overcome resistance to anticancer therapies and how this relates to the regulation of tumor microenvironmental stresses raises many issues. First, the question of whether we should try to enhance or inhibit autophagy in cancer treatment is not straightforward as it might vary according to cell type, the stress signal and other circumstances. What is needed to be better experimentally addressed include elucidating the impact of the tumor microenvironment on autophagy function, determining the role(s) of autophagy in the regulation of therapeutic sensitivity and defining novel mechanism by which autophagy inhibition can overcome chemotherapy resistance and sensitize the tumor cells to anticancer therapy. Second, to maximize the potential to be applied for more stringent clinical study, new and reliable methods for measuring autophagy in clinical samples need to be developed. Third, the toxicities and minimal single-agent anticancer efficacy of CQ or HCQ have restricted its clinical application. New and exciting autophagy inhibitors are worthy of further investigation in the future. Thus, establishment of more effective and safe combinational therapeutic strategies using autophagy inhibitors will be necessary in the future. However, our increased understanding of the functional relevance of autophagy within the tumor microenvironment and ongoing dialogue between emerging laboratory and clinical research of targeting autophagy will hopefully provide a promising therapeutic strategy to circumvent resistance and enhance the effects of anticancer therapies for cancer patients.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This study is supported by grants from the National Natural Science Foundation of China (grants 81301891, 81272593, 81071651 and 81071963) and the Zhejiang Provincial Natural Science Foundation of China (grant LQ13H160008).

1. Ringborg U, Platz A. Chemotherapy resistance mechanisms. Acta Oncol 1996; 35: 76–80.
2. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multireg drug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–234.
3. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010; 12: 814–822.
4. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
5. Sui X, Jin L, Huang X, Geng S, He C, Hu X, p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy 2011; 7: 565–571.
6. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol 2009; 339: 1–32.
7. Mando Y, Kanazawa T, Sawaiya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726–734.
8. Mayotte P, Thotram R. Autophagy and cancer therapy. Cancer Biol Ther 2011; 11: 127–137.
9. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer chemotherapy. Nat Rev Clin Oncol 2011; 8: 528–539.
10. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010; 222: 3–12.
11. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell 2008; 15: 344–351.
12. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Biochem Biophys Res Commun 2012; 424: 124–131.
13. Tauchihiro K, Fuji S, Exumi H. Autophagy and cancer: dynamism of the metabolism of tumour cells and tissues. Cancer Lett 2009; 270: 130–138.
14. Hardie DG. AMPK and Raptor: matching cell growth to energy supply. Mol Cell 2008; 30: 263–265.
15. Yang Z, Jin L, Huang X, Geng S, He C, Hu X, the role of autophagy in cancer therapy. Ann Intern Med 2006; 144: 337–343.
16. Poole B, Okhuma S. Effect of weak bases on the intratrasosyal pH in mouse pentonal macrophages. J Cell Biol 1981; 90: 665–669.
32. NIlsson JR. Does chloroquine, an antimalarial drug, affect autophagy in Tetrahymena pyriformis? J Protozool 1992; 39: 9–16.

33. Gunja N, Roberts D, McCoubrie D, Lambert P, Jan A, Simcs DE et al. Survival after massive hydroxychloroquine overdose. Anesth Intensive Care 2009; 37: 130–133.

34. Sun WL, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from etoposide-induced apoptosis and facilitates etoposide-resistance development. Autophagy 2011; 7: 1035–1044.

35. Scherer PV, Penyamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT. Autophagy facilitates the progression of ERα-positive breast cancer cells to estrogen resistance. Autophagy 2009; 5: 405–403.

36. Maycotte P, Arzis S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8: 200–212.

37. Li J, Hou N, Faried A, Tsusumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010; 46: 1900–1909.

38. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 2010; 70: 7699–7709.

39. Rosell S, Caussé A, Marli, de Medina P, Piozit M, Denis V et al. MAPK14/p38α confers inotrope resistance to TP53-defective cells by inducing survival autophagy. Autophagy 2012; 8: 1098–1112.

40. de la Cruz-Morillo MA, Valero ML, Callejas-Calera JA, Azan-Gonzalez L, Melgar-Rojas P, Galán-Moya EM et al. F38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene 2012; 31: 1073–1085.

41. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y et al. Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, in an in vivo study. Anticancer Drugs 2012; 23: 675–682.

42. Liu D, Yang Y, Liu Q, Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous carcinoma cell lines. Med Oncol 2011; 28: 105–111.

43. O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant cancer cells from etoposide-induced apoptosis and facilitates etoposide-resistance development. Autophagy 2011; 7: 1035–1044.

44. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Xu Y et al. Autophagy and chemotherapy resistance. X Sui et al
85. Stanton MJ, Dutta S, Zhang H, Polavarapu NS, Leontovich AA, Hintscheid P et al. Autophagy control by the VEGF-CNRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 2013; 73: 165–171.
86. Weidhaas JB, Babar I, Nallur SM, Trang P, Rouss J, Boehm M et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67: 1111–1116.
87. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010; 23: 897–1003.
88. Yu T, Cao L, Wang L, Kang R, Lotze M, Tang D. microRNA-30A promotes autophagy in response to cancer therapy. Autophagy 2012; 8: 853–855.
89. Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P et al. Targeting microRNA-30a-mediated autophagy enhances in situ activity against human chronic myeloid leukemia cells. Leukemia 2012; 26: 1752–1760.
90. Zou Z, Wu L, Ding H, Wang Y, Zhang Y, Chen X et al. Autophagic cell death induced by temozolomide in a glioblastoma cell line. Cancer Lett 2013; 328: 414–4156.
91. Xu N, Zhang J, Shen C, Luo Y, Xia L, Xie S et al. Cisplatin-induced downregulation of mFlt-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012; 423: 826–831.
92. Huang Y, Chuang AY, Ratovitski EA. Phospho- and cell death upon cisplatin exposure. Cell Cycle 2011; 10: 3938–3947.
93. Enzernmüller S, González P, Debatin KM, Fülsd S. Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor NVP-BEZ235 with lysosome-mediated apoptosis. Anticancer Drugs 2012; 24: 14–19.
94. Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer 2013: 132: 2682–2693.
95. Boya P, González-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T et al. Mitochondrial membrane permeabilization as a critical step of lysosome-initiated autophagy induced by hydroxochloroquine. Oncogene 2003; 22: 3927–3936.
96. Xiong HY, Guo XL, Bu XX, Zhang SS, Ma NN, Song JR et al. Autophagic cell death induced by S-FU in Bax or PUMA deficient human colon cancer cell. Cancer Lett 2010; 286: 68–74.
97. Lee JY, Won AJ, Lee J, Jung JH, Yoon S, Lee BM et al. Molecular mechanism of SACHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 2012; 9: 881–893.
98. Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant uterine cancer cell growth through autophagic flux. Toxicol Lett 2013; 220: 267–276.
99. Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt’s lymphoma. Int J Cancer 2011; 128: 1712–1723.
100. Leng S, Hao Y, Du D, Xie S, Hong L, Gu H et al. Ursolic acid promotes cancer cell death by inducing Atg5-dependent autophagy. Int J Cancer 2013; e-pub ahead of print 16 July 2013; doi:10.1002/ijc.28301.
101. Ren SX, Shen J, Cheng AS, Lu L, Chan RL, Li ZJ et al. FK 16-derived from the anticancer peptide LL37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One 2013; 8: e63641.
102. Jossat E, Burekkel H, Noël G, Bischoff P. The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res 2013; 33: 1845–1851.
103. Guo WJ, Zhang YM, Zhang L, Huang B, Tao FF, Chen W et al. Novel monoclonal platinum (II) complex Mon-Pl induces apoptosis-dependent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin. Autophagy 2013; 9: 996–1008.
104. Tai WT, Shiu CW, Chen HL, Liu CY, Lin CS, Cheng AL et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013; 4: e4485.
105. Salazar M, Carracedo A, Salanueva U, Hernández-Tiedra S, Lorente M, Egia A et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009; 119: 1359–1372.
106. Donadelli M, Dando I, Zamboni T, Costanzo C, Dalla Pozza E, Scopoli MT et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011; 2: e1152.
107. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D’Alessandro A, Zolla L et al. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis 2013; 4: e684.
108. Vasa D, Salazar M, Oles-Herrero N, Güzman M, Velasco G, Díaz-Laveda I. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011; 18: 1099–1111.
109. Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Tabaeda E et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011; 10: 90–103.
110. Yun SM, Jung JH, Jeong SJ, Sohn EJ, Kim B, Kim SH et al. Tanshinone IIa induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70S6K in KBM-5 leukemia cells. Phytother Res 2013; e-pub ahead of print 27 June 2013; doi:10.1002/ptr.5015.
111. Koﬁl L, Kaza N, Coric T, Byer SJ, Brossier NM, Klocke BJ et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013; 73: 4385–4405.
112. Cai Y, Wan Z, Sun T, Shi Y, Sun Y, Huang P et al. Diarylquinoline compounds induce autophagy-associated cell death by inhibiting the Akt pathway and increasing reactive oxygen species in human nasopharyngeal carcinoma cells. Oncol Rep 2013; 29: 983–992.
113. Chang HW, Lee YS, Nam HY, Han MW, Kim HJ, Moon SY et al. Knockdown of J-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal 2013; 25: 839–847.
114. Franzetti E, Huang ZJ, Shi YX, Xie K, Deng XJ, Li JP et al. Autophagy precedes apoptosis during the remodeling of silkworm larval midgut. Apoptosis 2012; 17: 305–324.
115. Zhang N, Chen Y, Jiang R, Li E, Chen X, Xi Z et al. PARP and RIP1 are required for autophagy induced by 11-deoxyovertinib A, which precedes caspase-dependent apoptosis. Autophagy 2011; 7: 588–612.
116. Abe A, Yamada H, Moriya S, Miyazawa K. The J-carcinoline alkaloid harmol induces cell death via autophagy but not apoptosis in human non-small cell lung cancer A549 cells. Biol Pharm Bull 2011; 34: 1264–1272.
117. Yahiro K, Satoh M, Nakano M, Hisamatsu J, Isomoto H, Sap J et al. Low-density lipoprotein receptor-related protein-1 (LRP1) mediates autophagy and apoptosis caused by Helicobacter pylori VacA. J Biol Chem 2012; 287: 31104–31115.
118. Francisco R, Pérez-Perarnau A, Corte C, Gil J, Tauler A, Ambrosio S. Histone deacetylase inhibition induces autophagy and apoptosis in human neuroblastoma cells. Cancer Lett 2012; 318: 42–52.
119. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654–666.
120. Choi KS. Autophagy and cancer. Exp Mol Med 2012; 44: 109–120.
121. Bucher WJ, Laskow TC, Pavlik PJ, Lin HM, Lotze MT. Cell-mediated autophagy promotes cancer cell survival. Cancer Res 2012; 72: 2970–2979.